Spero Therapeutics (SPRO) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12-month target prices for Spero Therapeutics' shares. Their SPRO share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 288.9% from the stock's current price.
View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts.

Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has increased by 4.0% and is now trading at $1.80.
View the best growth stocks for 2023 here.

Spero Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 974,400 shares, a drop of 32.8% from the April 30th total of 1,450,000 shares. Based on an average daily trading volume, of 573,600 shares, the short-interest ratio is presently 1.7 days.
View Spero Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SPRO earnings forecast.

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings results on Thursday, March, 30th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.95. The firm had revenue of $47.44 million for the quarter, compared to analyst estimates of $1.60 million. Spero Therapeutics had a negative net margin of 50.18% and a negative trailing twelve-month return on equity of 51.35%.

ETFs with the largest weight of Spero Therapeutics (NASDAQ:SPRO) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Spero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Anson Funds Management LP (6.36%), Renaissance Technologies LLC (0.78%), Geode Capital Management LLC (0.64%), XTX Topco Ltd (0.23%), Group One Trading L.P. (0.00%) and Two Sigma Investments LP (0.06%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Sath Shukla and Timothy Keutzer.
View institutional ownership trends.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SPRO stock can currently be purchased for approximately $1.80.

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $94.63 million and generates $53.51 million in revenue each year. The company earns $-46,420,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

The company employs 146 workers across the globe.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.